Recurrent aphthous stomatitis (RAS) that recurs with multiple episodes each month — or that produces severe oral pain and difficulty eating — represents a clinical pattern for which structured drug therapy is appropriate.
Drug therapy is indicated for patients who experience multiple episodes of RAS each month and/or present with symptoms of severe oral pain and difficulty eating. These features identify the population that benefits from a targeted therapeutic approach.
The first-line approach centers on topical agents that coat and protect affected mucosal surfaces. The clinical goals are a decrease in symptoms, reduction in ulcer number and size, and longer disease-free intervals. The complete evidence-based regimen — including the full selection of agents and application protocol — is available via the link below.
Drug therapy is considered for patients who experience multiple episodes of RAS each month and/or present with symptoms of severe pain and difficulty in eating.
The topical agents are the first option of the treatment of RAS.
The aim of the treatment of RAS is to decrease symptoms; reduce ulcer number and size; increase disease-free periods.
View source ↗